Company intelligence / Profile preview

InSite Vision Inc.

Alameda, California, United States

Ownership: Public · SUNPHARMA
Development stage: Other

Overview

The company developed AzaSite (azithromycin ophthalmic solution) 1%, which was launched in the US market for bacterial conjunctivitis treatment. They also had ISV-502 in Phase 3 clinical trials for eye and eyelid infection and inflammation.

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Small moleculestopical drug delivery
Industry: Biotech

Partnerships

Inspire Pharmaceuticals (for US distribution of AzaSite)international partners in South Korea, South America (four countries), Turkey, and China

Beyond the preview

Go deeper on InSite Vision Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InSite Vision Inc..